Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,561.03
(
0.54%
)
US TECH 100
29,420.00
(
0.83%
)
Dow Jones
50,605.23
(
-0.08%
)
Brent Oil
92.76
(
0.34%
)
Bitcoin
73,579.43
(
-1.74%
)
News Focus
News Focus
Post# of 257651
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123032
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pcrutch post# 137461

Tuesday, 02/21/2012 10:35:25 AM

Tuesday, February 21, 2012 10:35:25 AM

Post# of 257651
Enanta’s NS5A inhibitor (EDP-239) was announced 2 years ago (#msg-47301187), and there was nary a peep about it until now. NVS’ back-ended deal looks much more reasonable than what other HCV suitors have been doing lately.

Enanta is also the developer of ABT’s ABT-450 PI (#msg-61757048).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today